Molecular imaging-guided gene therapy of gliomas

Handbook of Experimental Pharmacology

Volumn 185, Issue PART2, 2008, Pages 341-359

  Rueger, Maria A ^a,b,c,d   Winkeler, Alexandra ^a,b,c,d   Thomas, Anne V ^a,b,c,d   Kracht, Lutz W ^a,b,c,d   Jacobs, Andreas H ^a,b,c,d  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^b MAX PLANCK INSTITUTE   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d KLINIKUM FULDA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BRAIN TUMOR; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; GLIOMA; HUMAN; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; TREATMENT OUTCOME;

ANIMALS; BRAIN NEOPLASMS; DIAGNOSTIC IMAGING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIOMA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

EID: 52049123085     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-540-77496-9_15     Document Type: Article

References (109)

1. Aboagye EO, Bhujwalla ZM (1999) Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 59:80-84
2. Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca A (1999) Multimodal cancer treatment mediated by replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 59:3861-3865
3. Alauddin MM, Shahinian A, Gordon EM, Conti PS (2004a) Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model. Mol Imaging 3:76-84
4. Alauddin MM, Shahinian A, Park R, Tohme M, Fissekis JD, Conti PS (2004b) Synthesis and evaluation of 2-deoxy-2-18F-fluoro-5-fluoro-1-beta-D- arabinofuranosyluracil as a potential PET imaging agent for suicide gene expression. J Nucl Med 45:2063-2069
5. Barker FG, Chang SM, Valk PE, Pounds TR, Prados MD (1997) 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 79:115-126
6. Blasberg RG, Gelovani J (2002) Molecular-genetic imaging: a nuclear medicine-based perspective. Mol Imaging 1:280-300
7. Brock CS, Young H, O'Reilly SM et al (2000) Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 82:608-615
8. Chao ST, Suh JH, Raja S, Lee SY, Barnett G (2001) The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 96:191-197
9. Chenevert TL, Stegman LD, Taylor JM et al (2000) Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92: 2029-2036
10. Choi SR, Zhuang ZP, Chacko AM et al (2005) SPECT imaging of herpes simplex virus type1 thymidine kinase gene expression by [(123)I]FIAU(1). Acad Radiol 12:798-805
11. Chung JK, Kim K, Kim SK et al (2002) Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo-or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 29:176-182
12. Contag PR, Olomu IN, Stevenson DK, Contag CH (1998) Bioluminescent indicators in living mammals. Nat Med 4:245-247
13. Croteau D, Scarpace L, Hearshen D et al (2001) Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery 49:823-829
14. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256:1550-1552
15. de Vries EF, VaalburgW(2002) Positron emission tomography: measurement of transgene expression. Methods 27:234-241
16. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63:535-537
17. De Witte O, Levivier M, Violon P et al (1996) Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery 39:470-476
18. De Witte O, Goldberg I, Wikler D et al (2001) Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 95:746-750
19. Deng WP, Yang WK, Lai WF et al (2004) Non-invasive in vivo imaging with radiolabelled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 thymidine kinase and ganciclovir. Eur J Nucl Med Mol Imaging 31:99-109
20. Fulham MJ, Brunetti A, Aloj L, Raman R, Dwyer AJ, Di Chiro G (1995) Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. J Neurosurg 83:657-664
21. Galbraith SM, Maxwell RJ, Lodge MA et al (2003) Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21:2831-2842
22. Galldiks N, Kracht LW, Burghaus L et al (2006) Use of (11)C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 33:516-524
23. Gambhir SS, Barrio JR, Wu L et al (1998) Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J Nucl Med 39:2003-2011
24. Gambhir SS, Herschman HR, Cherry SR et al (2000) Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2:118-138
25. Glantz MJ, Hoffman JM, Coleman RE et al (1991) Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol 29:347-355
26. Goldman S, Levivier M, Pirotte B et al (1996) Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer 78:1098-1106
27. Gossmann A, Helbich TH, Kuriyama N et al (2002) Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 15:233-240
28. Green LA, Nguyen K, Berenji B et al (2004) A tracer kinetic model for 18F-FHBG for quantitating herpes simplex virus type 1 thymidine kinase reporter gene expression in living animals using PET. J Nucl Med 45:1560-1570
29. Hackman T, Doubrovin M, Balatoni J et al (2002) Imaging expression of cytosine deaminaseherpes virus thymidine kinase fusion gene (CD/TK) expression with [124I]FIAU and PET. Mol Imaging 1:36-42
30. Hakumaki JM, Poptani H, Sandmair AM, Yla-Herttuala S, Kauppinen RA (1999) 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. Nat Med 5:1323-1327
31. Harsh GR, Deisboeck TS, Louis DN et al (2000) Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J Neurosurg 92: 804-811
32. Hein PA, Eskey CJ, Dunn JF, Hug EB (2004) Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 25:201-209
33. Heiss WD, Pawlik G, Herholz K, Wagner R, Goldner H, Wienhard K (1984) Regional kinetic constants and cerebral metabolic rate for glucose in normal human volunteers determined by dynamic positron emission tomography of [18F]-2-fluoro-2-deoxy-D-glucose. J Cereb Blood Flow Metab 4:212-223
34. Heiss WD, Heindel W, Herholz K et al (1990) Positron emission tomography of fluorine-18-deoxyglucose and image-guided phosphorus-31 magnetic resonance spectroscopy in brain tumors. J Nucl Med 31:302-310
35. Herholz K, Wienhard K, Heiss WD (1990) Validity of PET studies in brain tumors. Cerebrovasc Brain Metab Rev 2:240-265
36. Herholz K, HeindelW, Luyten PR et al (1992) In vivo imaging of glucose consumption and lactate concentration in human gliomas. Ann Neurol 31:319-327
37. Herholz K, Pietrzyk U, Voges J et al (1993) Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 79:853-858
38. Herholz K, Holzer T, Bauer B et al (1998) 11C-methionine PET for differential diagnosis of lowgrade gliomas. Neurology 50:1316-1322
39. Herholz K, Kracht LW, HeissWD(2003) Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J Neuroimaging 13:269-271
40. Herminghaus S, Pilatus U, Moller-Hartmann W et al (2002) Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed 15: 385-392
41. Hollon T (2000) Researchers and regulators reflect on first gene therapy death. Nat Med 6:6
42. Jacobs AH, Breakefield XO, Fraefel C (1999a) HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: Part I. HSV-1 structure, replication and pathogenesis. Neoplasia 1:387-401
43. Jacobs AH, Breakefield XO, Fraefel C (1999b) HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: Part II. Vector systems and applications. Neoplasia 1:402-416
44. Jacobs AH, Dubrovin M, Hewett J et al (1999c) Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. Neoplasia 1:154-161
45. Jacobs AH, Voges J, Reszka R et al (2001) Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 358:727-729
46. Jacobs AH, Dittmar C, Winkeler A, Garlip G, Heiss WD (2002) Molecular imaging of gliomas. Mol Imaging 1:309-335
47. Jacobs AH, Voges J, Kracht LW et al (2003a) Imaging in gene therapy of patients with glioma. J Neurooncol 65:291-305
48. Jacobs AH, Winkeler A, Hartung M et al (2003b) Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes. Hum Gene Ther 14:277-297
49. Jacobs AH, Kracht LW, Gossmann A et al (2005a) Imaging in neurooncology. NeuroRx 2:333-347
50. Jacobs AH, Thomas A, Kracht LW et al (2005b) 18F-fluoro-L-thymidine and 11Cmethylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 46:1948-1958
51. Jacobs AH, Rueger MA, Winkeler A et al (2007) Imaging-guided gene therapy of experimental gliomas. Cancer Res 67:1706-1715
52. Kang KW, Min JJ, Chen X, Gambhir SS (2005) Comparison of [14C]FMAU, [3H]FEAU, [14C]FIAU, and [3H]PCV for monitoring reporter gene expression of wild type and mutant herpes simplex virus type 1 thymidine kinase in cell culture. Mol Imaging Biol 7:296-303
53. Kaschten B, Stevenaert A, Sadzot B et al (1998) Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 39:778-785
54. Kim EE, Chung SK, Haynie TP et al (1992) Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. Radiographics 12:269-279
55. Kim YJ, Dubey P, Ray P, Gambhir SS, Witte ON (2004) Multimodality imaging of lymphocytic migration using lentiviral-based transduction of a tri-fusion reporter gene. Mol Imaging Biol 6:331-340
56. Klatzmann D, Valery CA, Bensimon G et al (1998) A phase I/II study of herpes simplex virus type 1 thymidine kinase suicide gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 9: 2595-2604
57. Kleihues P, CaveneeWK (2000) Pathology and genetics of tumours of the nervous system (WHO). International Agency for Research on Cancer (IARC Press), Lyon Kracht LW, Friese M, Herholz K et al (2003) Methyl-[11C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 30:868-873
58. Kumar AJ, Leeds NE, Fuller GN et al (2000) Malignant gliomas: MR imaging spectrum of radiation therapy-and chemotherapy-induced necrosis of the brain after treatment. Radiology 217:377-384
59. Langen KJ, Muhlensiepen H, Holschbach M, Hautzel H, Jansen P, Coenen HH (2000) Transport mechanisms of 3-[123I]iodo-alpha-methyl-L-tyrosine in a human glioma cell line: comparison with [3H]methyl]-L-methionine. J Nucl Med 41:1250-1255
60. Lehnhardt FG, Bock C, Rohn G, Ernestus RI, Hoehn M (2005) Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed 18:371-382
61. Lidar Z, Mardor Y, Jonas T et al (2004) Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 100:472-479
62. Ludemann L, Hamm B, Zimmer C (2000) Pharmacokinetic analysis of glioma compartments with dynamic Gd-DTPA-enhanced magnetic resonance imaging. Magn Reson Imaging 18: 1201-1214
63. MacLaren DC, Gambhir SS, Satyamurthy N et al (1999) Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther 6:785-791
64. Mankoff DA, Dehdashti F, Shields AF (2000) Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia 2:71-88
65. Mardor Y, Roth Y, Lidar Z et al (2001) Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 61:4971-4973
66. Mardor Y, Roth Y, Ochershvilli A et al (2004) Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI. Neoplasia 6:136-142
67. Mariani L, Siegenthaler P, Guzman R et al (2004) The impact of tumour volume and surgery on the outcome of adults with supratentorial WHO grade II astrocytomas and oligoastrocytomas. Acta Neurochir (Wien) 146:441-448
68. Markert JM, Medlock MD, Rabkin SD et al (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867-874
69. Meyerand ME, Pipas JM, Mamourian A, Tosteson TD, Dunn JF (1999) Classification of biopsyconfirmed brain tumors using single-voxel MR spectroscopy. AJNR Am J Neuroradiol 20: 117-123
70. Morgan B, Thomas AL, Drevs J et al (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955-3964
71. Nelson SJ (2004) Magnetic resonance spectroscopic imaging. Evaluating responses to therapy for gliomas. IEEE Eng Med Biol Mag 23:30-39
72. Palu G, Cavaggioni A, Calvi P et al (1999) Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther 6:330-337
73. Papanastassiou V, Rampling R, Fraser M et al (2002) The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 9:398-406
74. Pauleit D, Floeth F, Tellmann L et al (2004) Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors. J Nucl Med 45:374-381
75. Phelps ME (2000) PET: the merging of biology and imaging into molecular imaging. J Nucl Med 41:661-681
76. Pirzkall A, McKnight TR, Graves EE et al (2001) MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol BiolPhys 50:915-928
77. Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K (2004) Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 31:1464-1470
78. Popperl G, Goldbrunner R, Gildehaus FJ et al (2005) O-(2-[18F] fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 32:1018-1025
79. Preston-Martin S (1999) Epidemiology. In Berger MS, Wilson CD (eds) The gliomas. Saunders, Philadelphia, pp 2-11
80. Provenzale JM, McGraw P, Mhatre P, Guo AC, Delong D (2004) Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging. Radiology 232:451-460
81. Rainov NG (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11:2389-2401
82. Ram Z, Culver KW, Oshiro EM et al (1997) Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3:1354-1361
83. Rampling R, Cruickshank G, Papanastassiou V et al (2000) Toxicity evaluation of replicationcompetent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7:859-866
84. Ray P, De A, Min JJ, Tsien RY, Gambhir SS (2004) Imaging tri-fusion multimodality reporter gene expression in living subjects. Cancer Res 64:1323-1330
85. Ribom D, Eriksson A, Hartman M et al (2001) Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer 92:1541-1549
86. Rogulski KR, Wing MS, Paielli DL, Gilbert JD, Kim JH, Freytag SO (2000) Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum.Gene Ther 11:67-76
87. Ross BD, Kim B, Davidson BL (1995) Assessment of ganciclovir toxicity to experimental intracranial gliomas following recombinant adenoviral-mediated transfer of the herpes simplex virus thymidine kinase gene by magnetic resonance imaging and proton magnetic resonance spectroscopy. Clin Cancer Res 1:651-657
88. Serganova I, Doubrovin M, Vider J et al (2004) Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res 64:6101-6108
89. Shand N, Weber F, Mariani L et al (1999) A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 10: 2325-2335
90. Shields AF, Grierson JR, Dohmen BM et al (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334-1336
91. Sinha S, Bastin ME, Wardlaw JM, Armitage PA, Whittle IR (2004) Effects of dexamethasone on peritumoural oedematous brain: a DT-MRI study. J Neurol Neurosurg Psychiatry 75: 1632-1635
92. Soghomonyan SA, Doubrovin M, Pike J et al (2005) Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK. Cancer Gene Ther 12:101-108
93. Sokoloff L, Reivich M, Kennedy C et al (1977) The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897-916
94. Sundaresan G, Paulmurugan R, Berger F et al (2004) MicroPET imaging of Cre-loxP-mediated conditional activation of a herpes simplex virus type 1 thymidine kinase reporter gene. Gene Ther 11:609-618
95. Tang BN, Sadeghi N, Branle F, De Witte O, Wikler D, Goldman S (2005) Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. J Neurooncol 71:161-168
96. Tjuvajev JG, Stockhammer G, Desai R et al (1995) Imaging the expression of transfected genes in vivo. Cancer Res 55:6126-6132
97. Tjuvajev JG, Finn R, Watanabe K et al (1996) Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res 56:4087-4095
98. Tjuvajev JG, Avril N, Oku T et al (1998) Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res 58:4333-4341
99. Tjuvajev JG, Joshi A, Callegari J et al (1999) A general approach to the non-invasive imaging of transgenes using cis-linked herpes simplex virus thymidine kinase. Neoplasia 1:315-320
100. Toda M, Rabkin SD, Martuza RL (1998) Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 9:2177-2185
101. Todo T, Rabkin SD, Sundaresan P et al (1999) Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 10:2741-2755
102. Vlassenko AG, Thiessen B, Beattie BJ, Malkin MG, Blasberg RG (2000) Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI. J Neurooncol 46:249-259
103. Voges J, Reszka R, Gossmann A et al(2003) Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 54:479-487
104. Vos MJ, Uitdehaag BM, Barkhof F et al (2003) Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology 60:826-830
105. Weissleder R, Moore A, Mahmood U et al (2000) In vivo magnetic resonance imaging of transgene expression. Nat Med 6:351-355
106. Wen B, Burgman P, Zanzonico P et al (2004) A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia. Eur J Nucl Med Mol Imaging 31:1530-1538
107. Wiebe LI, Knaus EE (2001) Enzyme-targeted, nucleoside-based radiopharmaceuticals for scintigraphic monitoring of gene transfer and expression. Curr Pharm Des 7:1893-1906
108. Wurker M, Herholz K, Voges J et al (1996) Glucose consumption and methionine uptake in lowgrade gliomas after iodine-125 brachytherapy. Eur J Nucl Med 23:583-586
109. Yaghoubi SS, Barrio JR, Namavari M et al (2005) Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography. Cancer Gene Ther 12:329-339